View ValuationMedix 将来の成長Future 基準チェック /06現在、 Medixの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Media 収益成長16.0%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Jun 19Medix Inc. to Report Q1, 2027 Results on Aug 12, 2026Medix Inc. announced that they will report Q1, 2027 results on Aug 12, 2026お知らせ • Jun 16Medix Inc. (TSE:331A) announces an Equity Buyback for 400,000 shares, representing 5.22% for ¥188 million.Medix Inc. (TSE:331A) announces a share repurchase program. Under the program, the company will repurchase up to 400,000 shares, representing 5.22% of its issued share capital (excluding treasury stock), for a total purchase price of ¥188 million. The shares will be repurchased at a price of ¥470 per share. The purpose of the program is to enable flexible capital policies that respond to changes in the business environment. As of March 31, 2026, the company had 7,667,500 issued shares (excluding treasury stock) and 412,500 treasury shares.Reported Earnings • May 19Full year 2026 earnings released: EPS: JP¥56.04 (vs JP¥106 in FY 2025)Full year 2026 results: EPS: JP¥56.04 (down from JP¥106 in FY 2025). Revenue: JP¥4.26b (up 2.3% from FY 2025). Net income: JP¥436.0m (down 46% from FY 2025). Profit margin: 10% (down from 19% in FY 2025). The decrease in margin was driven by higher expenses.お知らせ • May 14Medix Inc., Annual General Meeting, Jun 26, 2026Medix Inc., Annual General Meeting, Jun 26, 2026.Upcoming Dividend • Mar 23Upcoming dividend of JP¥15.00 per shareEligible shareholders must have bought the stock before 30 March 2026. Payment date: 12 June 2026. Trailing yield: 2.9%. Lower than top quartile of Japanese dividend payers (3.6%). Higher than average of industry peers (2.0%).分析記事 • Feb 16Why Investors Shouldn't Be Surprised By Medix Inc.'s (TSE:331A) Low P/EWith a price-to-earnings (or "P/E") ratio of 7.6x Medix Inc. ( TSE:331A ) may be sending bullish signals at the moment...Reported Earnings • Feb 11Third quarter 2026 earnings released: EPS: JP¥19.50 (vs JP¥27.25 in 3Q 2025)Third quarter 2026 results: EPS: JP¥19.50 (down from JP¥27.25 in 3Q 2025). Revenue: JP¥1.06b (down 8.8% from 3Q 2025). Net income: JP¥147.0m (down 29% from 3Q 2025). Profit margin: 14% (down from 18% in 3Q 2025). The decrease in margin was driven by lower revenue.お知らせ • Nov 29Medix Inc. to Report Q3, 2026 Results on Feb 10, 2026Medix Inc. announced that they will report Q3, 2026 results on Feb 10, 2026お知らせ • Sep 16Medix Inc. (TSE:331A) announces an Equity Buyback for 600,000 shares, representing 7.47% for ¥308.4 million.Medix Inc. (TSE:331A) announces a share repurchase program. Under the program, the company will repurchase up to 600,000 shares, representing 7.47% of its issued share capital (excluding treasury stock), for a total purchase price of ¥308.4 million. The shares will be repurchased at a price of ¥514 per share. The purpose of the program is to enable flexible capital policies that respond to changes in the business environment. As of September 16, 2025, the company had 8,030,000 issued shares (excluding treasury stock) and 50,000 treasury shares.お知らせ • Sep 05Medix Inc. (TSE:331A) agreed to acquire 76.91% stake in Star To Asia Co., Ltd from Findstar Co., Ltd., Teppei Fujiwara and Masao Liang for TWD 185 million.Medix Inc. (TSE:331A) agreed to acquire 76.91% stake in Star To Asia Co., Ltd from Findstar Co., Ltd., Teppei Fujiwara and Masao Liang for TWD 185 million on September 4, 2025. A cash consideration of TWD 144 million will be paid by Medix Inc. Medix Inc. will pay an earnout payment of TWD 41 million cash. As part of consideration, TWD 185 million is paid towards common equity of Star To Asia Co., Ltd. The transaction is subject to consummation of due diligence investigation. The expected completion of the transaction is September 30, 2025. The advisory fees is TWD 0.62 million.お知らせ • Sep 04Medix Inc. to Report Q2, 2026 Results on Nov 11, 2025Medix Inc. announced that they will report Q2, 2026 results on Nov 11, 2025お知らせ • May 31Medix Inc. to Report Q1, 2026 Results on Aug 12, 2025Medix Inc. announced that they will report Q1, 2026 results on Aug 12, 2025お知らせ • May 13Medix Inc., Annual General Meeting, Jun 27, 2025Medix Inc., Annual General Meeting, Jun 27, 2025.お知らせ • Mar 22Medix Inc. to Report Fiscal Year 2025 Results on May 13, 2025Medix Inc. announced that they will report fiscal year 2025 results on May 13, 2025お知らせ • Mar 19Medix Inc. has completed an IPO in the amount of ¥1.84 billion.Medix Inc. has completed an IPO in the amount of ¥1.84 billion. Security Name: Common Stock Security Type: Common Stock Securities Offered: 1,800,000 Price\Range: ¥800 Discount Per Security: ¥64 Security Name: Common Stock Security Type: Common Stock Securities Offered: 500,000 Price\Range: ¥800 Discount Per Security: ¥64 このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Medix は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測TSE:331A - アナリストの将来予測と過去の財務データ ( )JPY Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/20264,256436214252N/A12/31/20254,163517N/AN/AN/A9/30/20254,154531N/AN/AN/A6/30/20254,150639N/AN/AN/A3/31/20254,161803482499N/A3/31/20244,179489N/AN/AN/A3/31/20234,273401N/AN/AN/Aアナリストによる今後の成長予測収入対貯蓄率: 331Aの予測収益成長が 貯蓄率 ( 0.8% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: 331Aの収益がJP市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: 331Aの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: 331Aの収益がJP市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: 331Aの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 331Aの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YMedia 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/05 00:41終値2026/07/03 00:00収益2026/03/31年間収益2026/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Medix Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Jun 19Medix Inc. to Report Q1, 2027 Results on Aug 12, 2026Medix Inc. announced that they will report Q1, 2027 results on Aug 12, 2026
お知らせ • Jun 16Medix Inc. (TSE:331A) announces an Equity Buyback for 400,000 shares, representing 5.22% for ¥188 million.Medix Inc. (TSE:331A) announces a share repurchase program. Under the program, the company will repurchase up to 400,000 shares, representing 5.22% of its issued share capital (excluding treasury stock), for a total purchase price of ¥188 million. The shares will be repurchased at a price of ¥470 per share. The purpose of the program is to enable flexible capital policies that respond to changes in the business environment. As of March 31, 2026, the company had 7,667,500 issued shares (excluding treasury stock) and 412,500 treasury shares.
Reported Earnings • May 19Full year 2026 earnings released: EPS: JP¥56.04 (vs JP¥106 in FY 2025)Full year 2026 results: EPS: JP¥56.04 (down from JP¥106 in FY 2025). Revenue: JP¥4.26b (up 2.3% from FY 2025). Net income: JP¥436.0m (down 46% from FY 2025). Profit margin: 10% (down from 19% in FY 2025). The decrease in margin was driven by higher expenses.
お知らせ • May 14Medix Inc., Annual General Meeting, Jun 26, 2026Medix Inc., Annual General Meeting, Jun 26, 2026.
Upcoming Dividend • Mar 23Upcoming dividend of JP¥15.00 per shareEligible shareholders must have bought the stock before 30 March 2026. Payment date: 12 June 2026. Trailing yield: 2.9%. Lower than top quartile of Japanese dividend payers (3.6%). Higher than average of industry peers (2.0%).
分析記事 • Feb 16Why Investors Shouldn't Be Surprised By Medix Inc.'s (TSE:331A) Low P/EWith a price-to-earnings (or "P/E") ratio of 7.6x Medix Inc. ( TSE:331A ) may be sending bullish signals at the moment...
Reported Earnings • Feb 11Third quarter 2026 earnings released: EPS: JP¥19.50 (vs JP¥27.25 in 3Q 2025)Third quarter 2026 results: EPS: JP¥19.50 (down from JP¥27.25 in 3Q 2025). Revenue: JP¥1.06b (down 8.8% from 3Q 2025). Net income: JP¥147.0m (down 29% from 3Q 2025). Profit margin: 14% (down from 18% in 3Q 2025). The decrease in margin was driven by lower revenue.
お知らせ • Nov 29Medix Inc. to Report Q3, 2026 Results on Feb 10, 2026Medix Inc. announced that they will report Q3, 2026 results on Feb 10, 2026
お知らせ • Sep 16Medix Inc. (TSE:331A) announces an Equity Buyback for 600,000 shares, representing 7.47% for ¥308.4 million.Medix Inc. (TSE:331A) announces a share repurchase program. Under the program, the company will repurchase up to 600,000 shares, representing 7.47% of its issued share capital (excluding treasury stock), for a total purchase price of ¥308.4 million. The shares will be repurchased at a price of ¥514 per share. The purpose of the program is to enable flexible capital policies that respond to changes in the business environment. As of September 16, 2025, the company had 8,030,000 issued shares (excluding treasury stock) and 50,000 treasury shares.
お知らせ • Sep 05Medix Inc. (TSE:331A) agreed to acquire 76.91% stake in Star To Asia Co., Ltd from Findstar Co., Ltd., Teppei Fujiwara and Masao Liang for TWD 185 million.Medix Inc. (TSE:331A) agreed to acquire 76.91% stake in Star To Asia Co., Ltd from Findstar Co., Ltd., Teppei Fujiwara and Masao Liang for TWD 185 million on September 4, 2025. A cash consideration of TWD 144 million will be paid by Medix Inc. Medix Inc. will pay an earnout payment of TWD 41 million cash. As part of consideration, TWD 185 million is paid towards common equity of Star To Asia Co., Ltd. The transaction is subject to consummation of due diligence investigation. The expected completion of the transaction is September 30, 2025. The advisory fees is TWD 0.62 million.
お知らせ • Sep 04Medix Inc. to Report Q2, 2026 Results on Nov 11, 2025Medix Inc. announced that they will report Q2, 2026 results on Nov 11, 2025
お知らせ • May 31Medix Inc. to Report Q1, 2026 Results on Aug 12, 2025Medix Inc. announced that they will report Q1, 2026 results on Aug 12, 2025
お知らせ • May 13Medix Inc., Annual General Meeting, Jun 27, 2025Medix Inc., Annual General Meeting, Jun 27, 2025.
お知らせ • Mar 22Medix Inc. to Report Fiscal Year 2025 Results on May 13, 2025Medix Inc. announced that they will report fiscal year 2025 results on May 13, 2025
お知らせ • Mar 19Medix Inc. has completed an IPO in the amount of ¥1.84 billion.Medix Inc. has completed an IPO in the amount of ¥1.84 billion. Security Name: Common Stock Security Type: Common Stock Securities Offered: 1,800,000 Price\Range: ¥800 Discount Per Security: ¥64 Security Name: Common Stock Security Type: Common Stock Securities Offered: 500,000 Price\Range: ¥800 Discount Per Security: ¥64